A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION

Update Il y a 5 ans
Reference: EUCTR2008-005885-30

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of this study is to evaluate the efficacy of sitaxsentan (100 mg dose) as compared to placebo in the treatment of subjects with PAH for 12 weeks, as determined by change from the Baseline 6MWD to Week 12.


Inclusion criteria

  • pulmonary arterial hypertension